Bausch Health Companies Inc. (NYSE:BHC) Given Consensus Recommendation of “Buy” by Analysts

Bausch Health Companies Inc. (NYSE:BHCGet Rating) has been assigned an average recommendation of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $31.33.

A number of research firms recently issued reports on BHC. Zacks Investment Research raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a research note on Tuesday, January 4th. Royal Bank of Canada cut their price objective on shares of Bausch Health Companies from $40.00 to $34.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 1st. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Tuesday, March 29th. Finally, TheStreet cut shares of Bausch Health Companies from a “c-” rating to a “d+” rating in a research report on Monday, March 28th.

Bausch Health Companies stock traded up $0.47 during mid-day trading on Tuesday, reaching $21.49. 99,566 shares of the company’s stock traded hands, compared to its average volume of 3,875,503. The company has a market cap of $7.72 billion, a price-to-earnings ratio of -7.96, a PEG ratio of 0.42 and a beta of 1.60. The stock has a 50 day moving average of $23.46 and a two-hundred day moving average of $25.42. Bausch Health Companies has a 12-month low of $20.70 and a 12-month high of $34.50.

Bausch Health Companies (NYSE:BHCGet Rating) last released its quarterly earnings results on Wednesday, February 23rd. The company reported $1.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.19. The company had revenue of $2.20 billion for the quarter, compared to the consensus estimate of $2.21 billion. Bausch Health Companies had a negative net margin of 11.24% and a negative return on equity of 708.85%. Bausch Health Companies’s revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.33 earnings per share. As a group, sell-side analysts forecast that Bausch Health Companies will post 4.5 earnings per share for the current year.

In other news, insider Joseph F. Gordon sold 3,889 shares of the firm’s stock in a transaction that occurred on Tuesday, March 8th. The shares were sold at an average price of $21.76, for a total transaction of $84,624.64. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Robert Spurr sold 1,595 shares of Bausch Health Companies stock in a transaction that occurred on Thursday, April 14th. The shares were sold at an average price of $22.19, for a total transaction of $35,393.05. Following the transaction, the insider now directly owns 90,506 shares in the company, valued at $2,008,328.14. The disclosure for this sale can be found here. Insiders have sold a total of 16,668 shares of company stock valued at $378,570 in the last quarter. 13.75% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of BHC. FMR LLC increased its holdings in Bausch Health Companies by 14.4% during the first quarter. FMR LLC now owns 312,264 shares of the company’s stock valued at $7,704,000 after buying an additional 39,276 shares during the period. Amundi Pioneer Asset Management Inc. boosted its stake in Bausch Health Companies by 123.0% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 202,426 shares of the company’s stock valued at $5,000,000 after acquiring an additional 111,654 shares in the last quarter. SG Americas Securities LLC boosted its stake in Bausch Health Companies by 532.1% in the third quarter. SG Americas Securities LLC now owns 1,264,017 shares of the company’s stock valued at $35,203,000 after acquiring an additional 1,064,041 shares in the last quarter. ING Groep NV acquired a new stake in Bausch Health Companies in the third quarter valued at approximately $55,700,000. Finally, Cambridge Investment Research Advisors Inc. boosted its stake in Bausch Health Companies by 5.9% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 15,249 shares of the company’s stock valued at $425,000 after acquiring an additional 844 shares in the last quarter. 71.26% of the stock is currently owned by institutional investors.

Bausch Health Companies Company Profile (Get Rating)

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.

Read More

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.